Kelber Olaf, Wegener Tankred, Steinhoff Barbara, Staiger Christiane, Wiesner Jacqueline, Knöss Werner, Kraft Karin
Kooperation Phytopharmaka GbR, 53173 Bonn, Germany(2).
Federal Institute for Drugs and Medical Devices (BfArM), 53175 Bonn, Germany(3).
Phytomedicine. 2014 Jul-Aug;21(8-9):1124-9. doi: 10.1016/j.phymed.2014.04.003. Epub 2014 May 16.
An assessment of genotoxicity is a precondition for marketing authorization respectively registration of herbal medicinal products (HMPs), as well as for inclusion into the 'Community list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products' established by the European Commission in accordance with Directive 2001/83/EC as amended, and based on proposals from the Committee on Herbal Medicinal Products (HMPC). In the 'Guideline on the assessment of genotoxicity of herbal substances/preparations' (EMEA/HMPC/107079/2007) HMPC has described a stepwise approach for genotoxicity testing, according to which the Ames test is a sufficient base for the assessment of genotoxicity in case of an unequivocally negative result. For reducing efforts for testing of individual herbal substances/preparations, HMPC has also developed the 'guideline on selection of test materials for genotoxicity testing for traditional herbal medicinal products/herbal medicinal products' (EMEA/HMPC/67644/2009) with the aim to allow testing of a standard range of test materials which could be considered representative of the commonly used preparations from a specific herbal drug according to a 'bracketing/matrixing' approach. The purpose of this paper is to provide data on the practical application of this bracketing and matrixing concept using the example of Valerianae radix, with the intention of facilitating its inclusion in the "Community list". Five extraction solvents, representing the extremes of the polarity range and including also mid-range extraction solvents, were used, covering the entire spectrum of phytochemical constituents of Valerianae radix, thereby including polar and non-polar constituents. Extracts were tested in the Ames test according to all relevant guidelines. Results were unequivocally negative for all extracts. A review of the literature showed that this result is in accordance with the available data, thus demonstrating the lack of a genotoxic potential. In conclusion the two guidelines on genotoxicity provide a practically applicable concept. Valerianae radix has no genotoxic potential, supporting its use in HMPs and its inclusion in the Community list.
遗传毒性评估是草药产品(HMPs)上市许可或注册的前提条件,也是将其纳入欧盟委员会根据经修订的2001/83/EC指令,并基于草药产品委员会(HMPC)的提议所制定的“传统草药产品所用草药物质、制剂及其组合的共同体清单”的前提条件。在“草药物质/制剂遗传毒性评估指南”(EMEA/HMPC/107079/2007)中,HMPC描述了遗传毒性测试的逐步方法,根据该方法,若Ames试验结果明确为阴性,则足以作为遗传毒性评估的基础。为减少对单个草药物质/制剂的测试工作量,HMPC还制定了“传统草药产品/草药产品遗传毒性测试试验材料选择指南”(EMEA/HMPC/67644/2009),目的是允许按照“分组/矩阵法”对一系列可被视为代表特定草药常用制剂的标准试验材料进行测试。本文旨在以缬草根为例,提供关于这种分组和矩阵概念实际应用的数据,以便于将其纳入“共同体清单”。使用了五种代表极性范围两端以及包括中等极性范围的提取溶剂,涵盖了缬草根植物化学成分的整个范围,从而包括极性和非极性成分。提取物按照所有相关指南进行Ames试验。所有提取物的结果均明确为阴性。文献综述表明,该结果与现有数据一致,从而证明其没有遗传毒性潜力。总之,这两项遗传毒性指南提供了一个实际可行的概念。缬草根没有遗传毒性潜力,支持其在草药产品中的使用及其纳入共同体清单。